Supplementary Figure 1: a) m^{6}A signals in the human and mouse *XPO1* gene retrieved from the Metdb v2 database[29]. Blue peaks correspond to meRIP-seq reads, yellow and green boxes are exons and UTR's respectively. Location of the CD-associated rs3087898 SNP is marked in the human transcript. **b)** Secondary structure of both forms of the human *XPO1* 5'UTR as predicted using the Vienna package[30]. **c)** m^{6}A RNA immunoprecipitation (meRIP) followed by RT-qPCR of the 5'UTR of *XPO1* and positive and negative controls in HCT116 intestinal and Jurkat T cell lines, n=3-5. (****$p<0.0001$; ns: non-significant according to a two-way ANOVA test. Enrichment relative to control IgG #$p<0.05$, ###$p<0.001$, ####$p<0.0001$ according to a two-way ANOVA test). **d)** Left, m^{6}A levels in the 5'UTR of *XPO1* in RNA extracted from human intestinal biopsies as assessed by meRIP-qPCR, n=3. (****$p< 0.0001$, according to a 2-tailed Student's t-test). Right, m^{6}A RNA immunoprecipitation (meRIP) followed by RT-qPCR of the 5'UTR of *XPO1* in immune (CD45+) and epithelial (CD326+) fractions from human intestinal biopsies, n=pool of 18 individuals. (**$p<0.01$ according to a two-way ANOVA test. Enrichment relative to control IgG #$p<0.05$, ns: non-significant according to a two-way ANOVA test). **e)** m^{6}A-RT-qPCR of the 3 m^{6}A motifs in the 5'UTR of *XPO1* and positive and negative controls in intestinal cells, n=4. Significance was calculated relative to the negative control. (*$p<0.05$,**$p<0.01$ according to a one-way ANOVA test). **f)** Cellular localization of both *XPO1* mRNA forms *XPO1*C* (C) and *XPO1*T* (T) and *PO* (cytoplasmic) and *MALAT1* (nuclear) controls, n=4. (ns: non-significant according to a one-way ANOVA test). **g)** mRNA stability of both *XPO1* mRNA forms *XPO1*C* (C) and *XPO1*T* (T) in cells treated with actinomycin D for 3 h and 6 h, n=3. (ns: non-significant according to a two-way ANOVA test). All values are means ± SEM.

Supplementary Figure 2: a) Relative expression of *METTL3* measured by RT-qPCR and **b)** overall m^{6}A RNA levels measured by ELISA in cells transfected with an empty vector (EV) and a vector overexpressing METTL3 (ovMETTL3), n=3. (*$p<0.05$, ****$p<0.0001$ according to a two-tailed Student's t-test). **c-d)** Relative RNA expression measured by RT-qPCR and quantitative summary of the of *METTL3* and *YTHDF1* immunoblot in Figure 2B, (***$p<0.001$, ****$p<0.0001$ according to a two-tailed Student's t-test). **e)** overall m^{6}A RNA levels measured by ELISA, (+$p<0.1$, ns:non-significant according to a two-tailed Student's t-test). **f)** m^{6}A RNA immunoprecipitation (meRIP) followed by RT-qPCR of the 5'UTR of *XPO1* (*$p<0.05$; ns: non-significant according to a two-way ANOVA test. Enrichment relative to control IgG +$p<0.1$,

#p<0.05, ##p<0.01 according to a two-way ANOVA test) and **g)** quantitative summary of the XPO1 immunoblot in Figure 2C, n=3-4. (*p<0.05 according to a two-tailed Student's t-test). **h-i)** METTL3 and YTHDF1 immunoprecipitation RT-qPCR values for *XPO1* 5'UTR and m^{6}A positive and negative controls, n=3-4. (Enrichment relative to control IgG +p<0.1, #p<0.05, ###p<0.001, ####p<0.0001, ns: non-significant according to a two-way ANOVA test). **j)** m^{6}A immunoprecipitation (meRIP) RT-qPCR values for *XPO1* 5'UTR and m^{6}A positive and negative controls in C26 mouse intestinal cells, n=3. (ns: non-significant according to a two-way ANOVA test. Enrichment relative to control IgG ###p<0.001 according to a two-way ANOVA test). **k)** Relative expression measured by RT-qPCR and quantitative summary of YTHDF1 immunoblot in Figure 2E and **l)** relative expression of *Xpo1* measured by RT-qPCR in WT (+/-) and *Ythdf1* knockout mice (DF1 KO), n=7. (**p<0.01, ***p<0.001, ns: non-significant according to a two-tailed Mann Whitney test). All values are means ± S.E.M.

Supplementary Figure 3: a) Schematic representation of the gliadin treatment set up *in vitro* (top) and *in vivo* (bottom). **b)** Left, overall m^{6}A RNA levels measured by m^{6}A Dotblot in cells, n=4. Right, quantitative summary of immunoblot in Figure 3A for XPO1, YTHDF1 and METTL3 in HCT116 cells, n=4. (+p<0.1, *p<0.05, **p<0.01, according to a two-tailed Student's t-test). **c)** Quantitative summary of XPO1 and YTHDF1 immunoblot in Figure 3C, n=3. (+p<0.1, ns:non-significant, according to a one-tailed Student's t-test). Silencing efficiency compared to NT cells (#p<0.05, according to a one-tailed Student's t-test). **d)** Left, overall m^{6}A RNA levels measured by m^{6}A Dotblot in WT control (NT) or PTG-treated mice (PTG), n=7. Right, quantitative summary of immunoblot in Figure 3D for XPO1 and YTHDF1 , n=7 (+p<0.1, *p<0.05, ns: non-significant according to a one-tailed Mann Whitney test). **e)** Left, overall m^{6}A RNA levels measured by m^{6}A Dotblot in humanized HLA-DR3-DQ2 control (NT) or PTG-treated mice (PTG). Right, quantitative summary of immunoblot in Figure 3D for XPO1 and YTHDF1, n=2-5 (+p<0.1, ns: non-significant according to a one-tailed Mann Whitney test). **f)** Quantitative summary of immunoblot in Figure 3F for YTHDF1 and XPO1 in untreated (-) and PTG-treated cells (+PTG) derived from wild type (WT) or *Ythdf1* KO (KO) mice, n=2-4 (+p<0.1, ns:non-significant according to a one-way ANOVA test). All values are means ± S.E.M.

Supplementary Figure 4: a) Quantitative summary of immunoblot in Figure 4A for XPO1 and p50 in cells transfected with an empty vector (EV) and overexpressing both forms of *XPO1* (C

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Gut

and T), n=3. (*$p<0.05$, ***$p<0.001$ according to a two-way ANOVA test). **b)** Relative expression measured by RT-qPCR of *XPO1* and *IL8* in cells transfected with an empty vector (EV), overexpressing both forms of *XPO1* (C and T) and cells overexpressing *XPO1* and treated with the NFkB inhibitor Bay (T+BAY), n=3. (***$p<0.001$, ****$p<0.0001$, ns: non-significant according to a two-way ANOVA test). **c)** Representative immunoblot and quantitative summary of the immunoblot for XPO1 and p50 in untreated cells (NT) and cells treated with PTG, n=4. (*$p<0.05$, **$p<0.01$ according to a two-tailed Student's t-test). **d)** Quantitative summary of immunoblot in Figure 4F for YTHDF1, XPO1 and p50 in untreated cells (NT), cells treated with PTG and cells treated with PTG + silenced for YTHDF1 (PTG+siYTH), n=3. (+$p<0.1$, ns: non-significant according to a one-tailed Student's t-test). Silencing efficiency compared to NT cells (#$p<0.05$, according to a one-tailed Student's t-test). **e)** Quantitative summary of immunoblot in Figure 4G for XPO1 and p50 in untreated cells (NT), cells treated with PTG and cells treated with + *XPO1* function inhibitor leptomycin B (PTG+LMB), n=3. (+$p<0.1$, *$p<0.05$, ns: non-significant according to a two-way ANOVA test). **f)** Relative expression measured by RT-qPCR of *XPO1* and *IL8* in untreated cells (NT), cells treated with PTG and cells treated with PTG and *XPO1* function inhibitor leptomycin B (PTG+LMB), n=3. (*$p<0.05$, ****$p<0.0001$, ns: non-significant according to a two-way ANOVA test). Quantitative summary of immunoblot for p50 protein in **g)** WT and **h)** humanized HLA-DR3-DQ2 control mice (NT) or PTG-treated mice (PTG) in Figure 4J and K, respectively. n=7 and n=2-3 (*$p<0.05$ according to a one-tailed Mann Whitney test). **i)** Relative expression measured by RT-qPCR of mouse *IL8* functional homolog cytokine *Cxcl1* in untreated (-) and PTG-treated cells (+PTG) derived from wild type (WT) or *Ythdf1* KO (KO) mice, n=2-4. All values are means ± S.E.M.

Supplementary Figure 5: a) Expression quantitative trait loci (eQTL) of *XPO1* expression levels compared between individuals with the protection genotype (CC) and individuals harboring the risk allele (CT+TT) n=7-25. Values are means ± S.E.M. (ns: non-significant, according to a two-tailed Mann Whitney test). **b)** RNA was extracted from untreated and PTG incubated biopsies and expression of *XPO1*, *METTL3* and *YTHDF1* was measured by RT-qPCR, n=15. Values are means of induction ± S.E.M. (+$p<0.1$, ns: non-significant according to a one-tailed Mann Whitney test). **c)** Correlation of the induction between *YTHDF1* and *XPO1* in PTG treated biopsies. Triangles correspond to *XPO1* mRNA and dots to XPO1 protein induction. n=9-15, R and p were calculated by Pearson correlation.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Gut

Supplementary Table1. List of used qPCR primers.

Gene	Primer Sequence
XPO1 (5'UTR)	Fw: TGTTCCAGTCTTTGCTGCTG
	Rv: AAGGCTCGCCTAAACTTTCC
METTL3	Fw: TCGAGAGCGAAATTTTTCAAC
	Rv: GGAGATAGAGAGCCTTCTGAACC
YTHDF1	Fw: ACCTGTCCAGCTATTACCCG
	Rv: TGGTGAGGTATGGAATCGGAG
HPRT	Fw: ACCAGTCAACAGGGGACATAA
	Rv: CTTCGTGGGGTCCTTTTCACC
TUG1	Fw: ATTCCACGACCATGGTTGTC
	Rv: ATTCACCACCAACCACACAG
SOCS1	Fw: AGACCCCTTCTCACCTCTTG
	Rv: AGTTAAGCTGCTACAACAACCAG
IL8	Fw: ACTGAGAGTGATTGAGAGTGGAC
	Rv: AACCCTCTGCACCCAGTTTTC
5'UTR Xpo1	Fw: GGTGGGAAAACTGTGAAACCC
	Rv: ACTGCTTCTTCCTTCCTTGTCC
Ythdf1-/-	Fw: CCTGCATTCTCAGCATGG
	Rv: GCTCCAGACTGTTCATCC
Hprt	Fw: CTGGTGAAAAGGACCTCTCGAAG
	Rv: CCAGTTTCACTAATGACACAAACG
Mip2a	Fw: CCAACCACCAGGCTACAGG
	Rv: GCGTCACACTCAAGCTCTG
Cxcl1	Fw: CTGGGATTCACCTCAAGAACATC
	Rv: CAGGGTCAAGGCAAGCCTC

Supplementary Table 2. List of used qPCR assays.

Gene	Assay ID
XPO1	C__16006954_10
MALAT1	Hs00273907_s1
RPLPO	Hs99999902_m1
Mettl3	Mm01316319_m1
Ythdf1	Mm00620538_m1
Rplpo	Mm00725448_s1

Supplementary Table 3. List of human biopsy samples.

	Dx	ORIGIN	AGE (years)	SEX	HLA	Serology	Marsh (0-3)
ADULT INDIVIDUALS	**CD (n=6)**	100% USA	34.2 ± 19.5	83.3% FEMALE		100% +	100% 3
				16.7% MALE			
	CTR (n=22)	31.8% USA	45.2 ± 11.3	77.3% FEMALE	13.6% DQ2	100% -	100% 0
		68.2% SPAIN		22.7% MALE	4.5% DQ8		
	GFD (n=6)	100% USA	37.3 ± 11.4	33.3% FEMALE		100% -	83.3% 0
				66.7% MALE			16.7% 1
	Dx	ORIGIN	AGE (years)	SEX	HLA	Serology	Marsh (0-3)
PEDIATRIC INDIVIDUALS	**CD (n=28)**	100% SPAIN	4.6 ± 3.7	48.5 FEMALE	69.7% DQ2	81.8% +	20% 0
				51.5 % MALE	9.1% DQ2/DQ8	12.1% -	80% 3
	CTR (n=16)	100% SPAIN	8.1± 3.6	68.75% FEMALE	-	100% -	100% 0
				31.25% MALE			
	GFD (n=12)	100% SPAIN	2 ± 0.7	69.2% FEMALE	69.2% DQ2	7.7% +	84.6% 0
				30.8% MALE	23.1% DQ2/DQ8	92.3% -	7.7% 1
							7.7% 3